SeaStar Medical Holding Corporation Common Stock
ICUSeaStar Medical Holding Corporation (ICU) specializes in developing and commercializing medical devices aimed at improving patient outcomes in critical care settings. The company focuses on innovative solutions for acute kidney injury and other critical conditions, leveraging advanced technologies to support better fluid management and renal function.
Company News
PepGen Inc. experienced a significant 112.4% pre-market stock surge after announcing an underwritten public offering of common stock and pre-funded warrants. Several other stocks showed notable pre-market movements, with some gaining and others declining.
SeaStar Medical announced progress in its NEUTRALIZE-AKI pivotal trial for acute kidney injury treatment, reaching over 60% enrollment with 125 of 200 anticipated patients and 16 clinical trial sites activated.
SeaStar Medical, a commercial-stage healthcare company, announced that it will report its Q1 2025 financial results and host a conference call on May 14, 2025. The company's Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA.
SeaStar Medical Holding Corporation, a healthcare company focused on transforming treatments for critically ill patients, announced that it will report its fourth quarter and year-end 2024 financial results on March 27, 2025, and host a webcast and conference call to discuss its financial results and business progress.
SeaStar Medical Holding Corporation announced that a 14th site has been activated for its NEUTRALIZE-AKI pivotal trial, which is evaluating the safety and efficacy of its Selective Cytopheretic Device (SCD) in treating acute kidney injury (AKI) in intensive care unit patients. The company estimates a significant market opportunity for the SCD in ...
